&w=3840&q=100)
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24.
INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose.
Consistent safety profile supports regulatory case
Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified.
ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities.
Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals.
Targeting IL-23 in chronic inflammatory pathways
ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk.
Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed.
Strategic pipeline strengthens global presence
Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Indian intervention ensured safety of Axiom-4 astronauts: Isro chief
Trichy: Indian intervention led to the postponement of the Axiom Mission 4 launch originally scheduled for July 11, ensuring the safety of astronaut Shubanshu Shukla and three others, chairman of the Indian Space Research Organisation ( Isro ) and secretary of the department of space, V Narayanan, has said. Speaking at the 21st convocation of the National Institute of Technology, Trichy (NIT-T) here on Saturday, Narayanan recalled the original launch of Axiom Mission 4 was scheduled for June 11, but on the morning of June 10, a liquid oxygen leak in the booster engine of the rocket was detected. "The rocket, which was supposed to take into space along with Shubanshu Shukhla and three other astronauts from different countries, had developed a problem. It was the Indian team that raised concerns and ensured the launch was called off on the evening of June 10 at 5.15pm, as the rocket was deemed unsafe to fly. The cracks were later fixed, and the rocket successfully lifted off on June 25, placing all the astronauts safely in orbit," he said. "Every Indian must be proud that, through our education system, knowledge, and the support of Isro, we were able to call off a mission in time to ensure the safety of the astronauts. Today, it is part of history that they were launched and brought back safely," he added. The Isro chairman also presented a model of the GSLV Mk-3 rocket to the institution. Praising India's space efforts, he said, "We have so far launched six rockets, with the heaviest being the GSLV Mark-3 vehicle, through which we placed Chandrayaan-2 and Chandrayaan-3 in orbit, completed commercial missions, and launched 72 foreign satellites. The same rocket is now set to lift a 6,500kg communication satellite of the USA into orbit. It will also carry Indian crew members to space in 2027." NIT-T director G Aghila presented a report about the academic, research accomplishments and reiterated its 9th ranking in NIRF and 31st among all higher education institutions. A total of 2,045 degrees were awarded which includes 175 Phd, 5 MS, 483 MTech, 18 M Arch, 95 MBA, 109 MCA, 90 17 M A, 995 B tech and 58 B Arch. Earlier, speaking to reporters at Trichy airport, Narayanan said, "On July 30, the NASA-Isro synthetic aperture radar satellite will be launched using GSLV mark 2 vehicle. The satellite is jointly realised by India, Isro and JPL (USA). This satellite is going to be useful for the global community in earth observation and disaster mitigation areas. It is an important satellite, and it will be the 102nd launch from Indian soil. "
New Indian Express
8 hours ago
- New Indian Express
HIV prevention: Gilead's vaccine breakthrough nears EU approval
CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still rapidly spreading HIV epidemic, in the world with the European Medicines Agency's (EMA) advisory committee issuing a positive opinion for its twice-yearly injectable, lenacapavir. EMA the decision on Thursday (July 24) clears the way for approval by the European Commission later this year, following similar regulatory clearance in the United States in June 2025. Lenacapavir, a HIV pre-exposure prophylaxis (PrEP), is to be marketed in Europe under the brand name Yeytuo, is a long-acting injectable designed to prevent HIV infection with just two subcutaneous doses annually, following an initial oral lead-in. This innovative therapy is part of a new class of HIV-1 capsid inhibitors that disrupt multiple stages of the viral replication cycle. It represents the first and only twice-yearly PrEP option for individuals at risk of HIV, offering a significant alternative to the currently available daily oral pills like Truvada (TDF/FTC). Clinical trials have demonstrated strong efficacy. In the PURPOSE 1 trial, conducted among over 5,000 cisgender women and adolescent girls in South Africa and Uganda, lenacapavir achieved 100% efficacy—zero new HIV infections were reported in the treatment group. A second trial, PURPOSE 2, involving a broader group of cisgender men, transgender, and non-binary adults, showed a 96% reduction in HIV risk compared to those on daily PrEP. These results prompted early unblinding of both trials due to overwhelming benefit. Participants also reported high satisfaction with the twice-yearly regimen, citing ease of adherence, reduced stigma, and fewer missed doses compared to daily pills. Gilead's chief medical officer, Dr. Dietmar Berger, was on Friday quoted in reports saying that lenacapavir 'has the potential to become a critical tool for public health,' especially for individuals who face barriers to consistent healthcare access. The product is expected to play a vital role in addressing rising HIV infections in Europe, where more than 24,700 new diagnoses were reported in 2023—an 11.8% increase from the previous year across the EU, Iceland, Liechtenstein, and Norway. Beyond Europe, Gilead is pursuing a global access strategy for lenacapavir. The company has licensed the drug for generic production in 120 low-and lower-middle-income countries and is working toward WHO prequalification and inclusion in international HIV prevention guidelines. It is also eligible for EU-M4all procedures, which would streamline regulatory pathways for resource-limited settings.
Hindustan Times
9 hours ago
- Hindustan Times
Surgeon explains how eating too fast can lead to bloating, poor digestion and overeating: ‘The speed at which you eat…'
From increased bloating to higher risks of obesity, eating too fast might be doing more harm than you realise. In his July 24 Instagram post, Dr Karan Rajan, an NHS surgeon and health content creator, explains how the speed at which you have your meals can impact your body and why taking your time might be the healthier choice. (Also read: NHS surgeon suggests easy ways to add 30 g fibre in your daily diet with fruits, veggies, nuts, seeds, legumes and more ) Surgeon highlights dangers of eating too quickly for gut health. (Freepik) What happens when you eat too fast "When you inhale your food like it's an Olympic sport, a few sneaky things happen," NHS surgeon Dr Rajan warns in his caption. Here's what he says goes wrong when you eat too fast: Dr Rajan explains in the video, "The speed at which you eat has a significant impact on your overall gut health. When you eat too fast, you can override multiple physiological mechanisms designed to optimise digestion. It all begins in the mouth, where the enzyme amylase starts breaking down carbohydrates." He adds, "If you're speed-running your lasagna and not chewing properly, food can reach your intestine in larger chunks. This gives your gut bacteria more undigested carbohydrates to work with, leading to excessive gas production. Plus, the more you chew, the better you support enzymatic digestion, which helps your system function more efficiently." Why should you slow down and chew more You skip the cephalic phase, which is the brain's way of prepping your body for digestion. As a result, fewer digestive enzymes and stomach acid are released. Your gut gets overwhelmed because nutrients arrive before the system is ready and primed to deal with them. Ghrelin (your hunger hormone) stays high, while satiety hormones like GLP-1 and PYY lag behind, so you end up feeling less full and more snacky later. "So the next time you eat, slow it down. Chew. Taste. Pretend you're at a Michelin-starred restaurant, not starring in an episode of Man vs Food," says Dr Rajan. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
